Morgan Stanley: 'we view the HDV program as promising and we view the transaction as a good fit for Mirum'
Tweet Send to a Friend
Morgan Stanley analyst Michael E Ulz reiterated an Overweight rating and $81.00 price target on Mirum Pharmaceuticals (NASDAQ: MIRM).The analyst ...
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
